MOB Stock Overview
A pharmaceutical company, develops and commercializes medical products primarily in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Moberg Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 33.78 |
| 52 Week High | SEK 40.90 |
| 52 Week Low | SEK 6.15 |
| Beta | 0.93 |
| 11 Month Change | -0.30% |
| 3 Month Change | -13.21% |
| 1 Year Change | 137.89% |
| 33 Year Change | -38.92% |
| 5 Year Change | -94.88% |
| Change since IPO | -88.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| MOB | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -7.5% | -1.8% | -4.2% |
| 1Y | 137.9% | 73.0% | 12.5% |
Return vs Industry: MOB exceeded the Swedish Pharmaceuticals industry which returned 73% over the past year.
Return vs Market: MOB exceeded the Swedish Market which returned 12.5% over the past year.
Price Volatility
| MOB volatility | |
|---|---|
| MOB Average Weekly Movement | 13.1% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: MOB's share price has been volatile over the past 3 months.
Volatility Over Time: MOB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 9 | Anna Ljung | www.mobergpharma.se |
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013.
Moberg Pharma AB (publ) Fundamentals Summary
| MOB fundamental statistics | |
|---|---|
| Market cap | SEK 1.58b |
| Earnings (TTM) | -SEK 22.56m |
| Revenue (TTM) | SEK 820.00k |
1,924x
P/S Ratio-69.9x
P/E RatioIs MOB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOB income statement (TTM) | |
|---|---|
| Revenue | SEK 820.00k |
| Cost of Revenue | SEK 328.00k |
| Gross Profit | SEK 492.00k |
| Other Expenses | SEK 23.05m |
| Earnings | -SEK 22.56m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 13, 2024
| Earnings per share (EPS) | -0.48 |
| Gross Margin | 60.00% |
| Net Profit Margin | -2,751.22% |
| Debt/Equity Ratio | 0% |
How did MOB perform over the long term?
See historical performance and comparison